Pure Global

Combination of Sotyktu and Enstilar for Plaque Psoriasis - Trial NCT06329258

Access comprehensive clinical trial information for NCT06329258 through Pure Global AI's free database. This Phase 4 trial is sponsored by Psoriasis Treatment Center of Central New Jersey and is currently Completed. The study focuses on Psoriasis. Target enrollment is 30 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06329258
Phase 4
Completed
drug
Trial Details
ClinicalTrials.gov • NCT06329258
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Combination of Sotyktu and Enstilar for Plaque Psoriasis
A Single Center Study to Evaluate the Effectiveness and Safety of SOTYKTU® (Deucravacitinib) in Combination With Enstilar® for Moderate to Severe Plaque Psoriasis

Study Focus

Psoriasis

Enstilar

Interventional

drug

Sponsor & Location

Psoriasis Treatment Center of Central New Jersey

East Windsor, United States of America

Timeline & Enrollment

Phase 4

Dec 06, 2022

Nov 13, 2023

30 participants

Primary Outcome

Psoriasis Area and Severity Index 75 at week 12

Summary

combination deucravacitinib and enstilar foam

ICD-10 Classifications

Psoriasis
Other psoriasis
Psoriasis, unspecified
Arthropathic psoriasis
Psoriasis vulgaris

Data Source

ClinicalTrials.gov

NCT06329258

Non-Device Trial